Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for SEVELAMER HYDROCHLORIDE
- A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients
- Colchicine and Inflammation in Hemodialysis Patients
- A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505 to Treat Hyperphosphatemia in Hemodialysis Patients
- Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
- Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat
- A Long-Term Study to Evaluate the Ability of Tenapanor Alone or in Combination With Sevelamer to Treat to Goal Serum Phosphorus in Patients With End-Stage Kidney Disease on Dialysis
- Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
- GLP-1-mediated Gluco-metabolic Effects of Bile Acid Sequestration
- PA21 Safety and Efficacy in Adult Chinese Subjects
- The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4
- Different Effects of Non-calcium Phosphate Binders on Serum Calcium
- A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
- DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis
- Hyperphosphatemia in Children With Chronic Kidney Disease
- The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis
- A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
- Risk Factors for Vascular Calcifications in Hemodialysis Patients: to What Extent is Vitamin K2 Deficiency Involved?
- A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy
- Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion
- An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic CKD Patients
- Optimal Anemia Treatment in End Stage Renal Disease (ERSD)
- PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs
- Phophate Lowering Trial
- Effect of Sevelamer on P-cresol Levels in CKD
- Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)
- Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)
- Effect of Bile Acid Sequestration on Postprandial GLP-1 Secretion, Glucose Homeostasis and Gut Microbiota
- Sevelamer in Proteinuric CKD
- Post Authorisation Safety Study of Renvela® in Chronic Kidney Disease Patients Not on Dialysis With Hyperphosphataemia
- How Bone is Made in Children Receiving Dialysis
- Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients
- Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis
- Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study
- An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease
- Sevelamer for Reducing Endotoxemia and Immune Activation
- The Effects of Sevelamer Carbonate on Diabetic Nephropathy
- A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients
- Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients
- A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
- Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4
- The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan
- FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease
- Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease
- Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)
- A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
- Hypophosphatemic Rickets in Norway
- Sevelamer Hydrochloride and Femoral and Carotid Intima Media Thickness Progression in End Stage Renal Disease
- Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients
- Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy
- The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination With Fosrenol or Renvela in Healthy Volunteers
- Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers
- Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis
- Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride
- Effect of Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure (CKD)
- A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis
- Effects of Phosphate Binding With Sevelamer in Stage 3 Chronic Kidney Disease
- A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD
- A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)
- Sevelamer Hydrochloride in Peritoneal Dialysis Patients
- Reduce Cardiovascular Calcifications to Reduce QT Interval in Dialysis
- Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis
- Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis
- A Multicenter, Active and Placebo-controlled Study of Enteric Coated Sevelamer in Patients With Mild to Moderate Hypercholesteremia
- An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis
- Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients
- Regulation of Bone Formation in Renal Osteodystrophy
- A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
- Sevelamer, Fetuin-A and Endothelial Dysfunction in CKD
- Efficacy of Phosphate Binding in Healthy Volunteers: Chewed Versus Crushed Lanthanum Carbonate
- Head to Head Study Against Sevelamer Hydrochloride
- Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate
- Arterial Stiffness and Calcifications in Haemodialysis Patients on Sevelamer or Calcium Acetate
- Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing
- Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis
- Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl Tablets in Haemodialysis Patients
- CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients
- Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis
- Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease
- Parathyroid Hormone Levels in Relation to the Phosphorus Content of Meals
Clinical trials list
click for details